Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

[Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].

Matsukawa J, Inatomi N, Nishida H, Tsukimi Y.

Nihon Yakurigaku Zasshi. 2018;152(3):104-110. doi: 10.1254/fpj.152.104. Japanese.

PMID:
30185727
2.

Appearances of Fukushima Daiichi Nuclear Power Plant-Derived 137Cs in Coastal Waters around Japan: Results from Marine Monitoring off Nuclear Power Plants and Facilities, 1983-2016.

Takata H, Kusakabe M, Inatomi N, Ikenoue T.

Environ Sci Technol. 2018 Mar 6;52(5):2629-2637. doi: 10.1021/acs.est.7b03956. Epub 2018 Feb 14.

PMID:
29336565
3.

Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2'-piperidin)-1-ones as potassium-competitive acid blockers.

Imaeda T, Ono K, Nakai K, Hori Y, Matsukawa J, Takagi T, Fujioka Y, Tarui N, Kondo M, Imanishi A, Inatomi N, Kajino M, Itoh F, Nishida H.

Bioorg Med Chem. 2017 Jul 15;25(14):3719-3735. doi: 10.1016/j.bmc.2017.05.012. Epub 2017 May 6.

PMID:
28522264
4.

Exploration of pyrrole derivatives to find an effective potassium-competitive acid blocker with moderately long-lasting suppression of gastric acid secretion.

Nishida H, Fujimori I, Arikawa Y, Hirase K, Ono K, Nakai K, Inatomi N, Hori Y, Matsukawa J, Fujioka Y, Imanishi A, Fukui H, Itoh F.

Bioorg Med Chem. 2017 Jul 1;25(13):3447-3460. doi: 10.1016/j.bmc.2017.04.034. Epub 2017 Apr 27.

PMID:
28483454
5.

Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action.

Nishida H, Arikawa Y, Hirase K, Imaeda T, Inatomi N, Hori Y, Matsukawa J, Fujioka Y, Hamada T, Iida M, Nishitani M, Imanishi A, Fukui H, Itoh F, Kajino M.

Bioorg Med Chem. 2017 Jul 1;25(13):3298-3314. doi: 10.1016/j.bmc.2017.04.014. Epub 2017 Apr 13.

PMID:
28442261
6.

Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.

Inatomi N, Matsukawa J, Sakurai Y, Otake K.

Pharmacol Ther. 2016 Dec;168:12-22. doi: 10.1016/j.pharmthera.2016.08.001. Epub 2016 Aug 8. Review.

7.

Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).

Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, Karashima M, Otsuka K, Inatomi N.

Adv Ther. 2016 Jul;33(7):1140-57. doi: 10.1007/s12325-016-0345-2. Epub 2016 Jun 10. Review.

PMID:
27287852
8.

The Contribution of Sources to the Sustained Elevated Inventory of (137)Cs in Offshore Waters East of Japan after the Fukushima Dai-ichi Nuclear Power Station Accident.

Takata H, Kusakabe M, Inatomi N, Ikenoue T, Hasegawa K.

Environ Sci Technol. 2016 Jul 5;50(13):6957-63. doi: 10.1021/acs.est.6b00613. Epub 2016 Jun 22.

PMID:
27282171
9.

Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.

Matsukawa J, Kogame A, Tagawa Y, Inatomi N.

Dig Dis Sci. 2016 Jul;61(7):1888-94. doi: 10.1007/s10620-016-4100-y. Epub 2016 Mar 9.

PMID:
26961787
10.

[Pharmacological and clinical profiles of a novel potassium-competitive acid blocker, vonoprazan fumarate (Takecab(®) 10 mg and 20 mg)].

Matsukawa J, Inatomi N, Otake K.

Nihon Yakurigaku Zasshi. 2015 Nov;146(5):275-82. doi: 10.1254/fpj.146.275. Review. Japanese. No abstract available.

PMID:
26558313
11.

Synthetic studies of five-membered heteroaromatic derivatives as potassium-competitive acid blockers (P-CABs).

Arikawa Y, Hasuoka A, Nishida H, Hirase K, Inatomi N, Takagi T, Tarui N, Kawamoto M, Imanishi A, Itoh F, Kajino M.

Bioorg Med Chem Lett. 2015;25(10):2037-40. doi: 10.1016/j.bmcl.2015.03.094. Epub 2015 Apr 6.

PMID:
25891103
12.

Molecular modeling, design, synthesis, and biological activity of 1H-pyrrolo[2,3-c]pyridine-7-amine derivatives as potassium-competitive acid blockers.

Arikawa Y, Hasuoka A, Hirase K, Inatomi N, Sato F, Hori Y, Takagi T, Tarui N, Kawamoto M, Kajino M.

Chem Pharm Bull (Tokyo). 2014;62(4):336-42.

13.

The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.

Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR.

Aliment Pharmacol Ther. 2012 Nov;36(10):972-9. doi: 10.1111/apt.12059. Epub 2012 Sep 25.

14.

Effects of TAK-480, a novel tachykinin NK(2)-receptor antagonist, on visceral hypersensitivity in rabbits and ricinoleic acid-induced defecation in guinea pigs.

Tanaka T, Tanaka A, Nakamura A, Matsushita K, Imanishi A, Matsumoto-Okano S, Inatomi N, Miura K, Toyoda M, Mizojiri G, Tsukimi Y.

J Pharmacol Sci. 2012;120(1):15-25. Epub 2012 Aug 11.

15.

Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers.

Nishida H, Hasuoka A, Arikawa Y, Kurasawa O, Hirase K, Inatomi N, Hori Y, Sato F, Tarui N, Imanishi A, Kondo M, Takagi T, Kajino M.

Bioorg Med Chem. 2012 Jun 15;20(12):3925-38. doi: 10.1016/j.bmc.2012.04.014. Epub 2012 Apr 14.

PMID:
22579619
16.

Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).

Arikawa Y, Nishida H, Kurasawa O, Hasuoka A, Hirase K, Inatomi N, Hori Y, Matsukawa J, Imanishi A, Kondo M, Tarui N, Hamada T, Takagi T, Takeuchi T, Kajino M.

J Med Chem. 2012 May 10;55(9):4446-56. doi: 10.1021/jm300318t. Epub 2012 Apr 30.

PMID:
22512618
17.

Establishment and validation of a rabbit model for in vivo pharmacodynamic screening of tachykinin NK2 antagonists.

Tanaka T, Matsumoto-Okano S, Inatomi N, Fujioka Y, Kamiguchi H, Yamaguchi M, Imanishi A, Kawamoto M, Miura K, Nishikawa Y, Tsukimi Y.

J Pharmacol Sci. 2012;118(4):487-95. Epub 2012 Mar 22.

18.

Novel 3-phenylpiperidine-4-carboxamides as highly potent and orally long-acting neurokinin-1 receptor antagonists with reduced CYP3A induction.

Shirai J, Sugiyama H, Morimoto S, Maezaki H, Yamamoto Y, Okanishi S, Kamo I, Matsumoto S, Ishigami K, Inatomi N, Imanishi A, Kawamoto M, Tarui N, Hashimoto T, Ikeura Y.

Bioorg Med Chem. 2012 Jan 15;20(2):962-77. doi: 10.1016/j.bmc.2011.11.048. Epub 2011 Dec 1.

PMID:
22189275
19.

High-throughput screening of potassium-competitive acid blockers.

Kondo M, Kawamoto M, Hasuoka A, Kajino M, Inatomi N, Tarui N.

J Biomol Screen. 2012 Feb;17(2):177-82. doi: 10.1177/1087057111421004. Epub 2011 Sep 22.

PMID:
21940711
20.

Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).

Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G.

J Pharmacol Exp Ther. 2011 Nov;339(2):412-20. doi: 10.1124/jpet.111.185314. Epub 2011 Aug 9.

21.

A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.

Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N.

J Pharmacol Exp Ther. 2011 Jun;337(3):797-804. doi: 10.1124/jpet.111.179556. Epub 2011 Mar 16.

PMID:
21411494
22.

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.

Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N.

Biochem Pharmacol. 2011 May 1;81(9):1145-51. doi: 10.1016/j.bcp.2011.02.009. Epub 2011 Mar 1.

PMID:
21371447
23.

Plutonium isotopes concentration in seawater and bottom sediment off the Pacific coast of Aomori sea area during 1991-2005.

Oikawa S, Watabe T, Inatomi N, Isoyama N, Misonoo J, Suzuki C, Nakahara M, Nakamura R, Morizono S, Fujii S, Hara T, Kido K.

J Environ Radioact. 2011 Mar;102(3):302-10. doi: 10.1016/j.jenvrad.2010.12.007. Epub 2011 Jan 12.

PMID:
21227553
24.

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.

Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, Inatomi N.

J Pharmacol Exp Ther. 2010 Oct;335(1):231-8. doi: 10.1124/jpet.110.170274. Epub 2010 Jul 12. Erratum in: J Pharmacol Exp Ther. 2016 Jul;358(1):1-2.

PMID:
20624992
25.

[Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)].

Inatomi N, Nitta K, Sakurai Y.

Nihon Yakurigaku Zasshi. 2008 Feb;131(2):149-56. Review. Japanese. No abstract available.

PMID:
18277015
26.

Novelty stress increases fecal pellet output in mongolian gerbils: effects of several drugs.

Okano S, Nagaya H, Inatomi N.

J Pharmacol Sci. 2005 Aug;98(4):411-8. Epub 2005 Jul 29.

27.

Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors.

Masuda Y, Takatsu Y, Terao Y, Kumano S, Ishibashi Y, Suenaga M, Abe M, Fukusumi S, Watanabe T, Shintani Y, Yamada T, Hinuma S, Inatomi N, Ohtaki T, Onda H, Fujino M.

Biochem Biophys Res Commun. 2002 Apr 26;293(1):396-402.

PMID:
12054613
28.
29.

Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo.

Okano S, Nagaya H, Ikeura Y, Natsugari H, Inatomi N.

J Pharmacol Exp Ther. 2001 Aug;298(2):559-64.

PMID:
11454917
30.

Corrigendum to: EM574, an erythromycin derivative, improves delayed gastric emptying of semi-solid meals in conscious dogs

Sato F, Marui S, Inatomi N, Itoh Z, Omura S.

Eur J Pharmacol. 2000 Sep 22;404(3):397. No abstract available.

PMID:
10996606
31.

EM574, an erythromycin derivative, improves delayed gastric emptying of semi-solid meals in conscious dogs.

Sato F, Marui S, Inatomi N, Itoh Z, Omura S.

Eur J Pharmacol. 2000 Apr 28;395(2):165-72. Erratum in: Eur J Pharmacol 2000 Sep 22;404(3):397.

PMID:
10794824
32.

EM574, an erythromycin derivative, is a motilin receptor agonist in the rabbit.

Sato F, Sekiguchi M, Marui S, Inatomi N, Shino A, Itoh Z, Omura S.

Eur J Pharmacol. 1997 Mar 12;322(1):63-71.

PMID:
9088872
33.

Role of endogenous basic fibroblast growth factor in the healing of gastric ulcers in rats.

Satoh H, Shino A, Sato F, Asano S, Murakami I, Inatomi N, Nagaya H, Kato K, Szabo S, Folkman J.

Jpn J Pharmacol. 1997 Jan;73(1):59-71.

34.

[Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].

Inatomi N, Murakami I, Asano S, Inada I, Satoh H.

Nihon Yakurigaku Zasshi. 1996 Dec;108(6):333-43. Japanese.

PMID:
9017687
35.

[Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats].

Murakami I, Asano S, Yukishige K, Nagaya H, Satoh H, Inatomi N.

Nihon Yakurigaku Zasshi. 1996 Dec;108(6):323-32. Japanese.

PMID:
9017686
36.

Microbial conversion of EM574 and EM523, gastrointestinal motor stimulating agents.

Funabashi Y, Hakoda S, Inatomi N, Koyama K, Tanida S, Harada S, Itoh Z, Omura S.

J Antibiot (Tokyo). 1996 Aug;49(8):802-10.

37.

Bioactive metabolites of EM574 and EM523, erythromycin derivatives having strong gastrointestinal motor stimulating activity.

Funabashi Y, Maeshiba Y, Inatomi N, Tanayama S, Harada S, Itoh Z, Omura S.

J Antibiot (Tokyo). 1996 Aug;49(8):794-801.

38.

Vagus-dependent and vagus-independent mechanisms of action of the erythromycin derivative EM574 and motilin in dogs.

Inatomi N, Sato F, Marui S, Itoh Z, Omura S.

Jpn J Pharmacol. 1996 May;71(1):29-38.

39.

[Mechanism of increased gastric motility effect of EM523].

Shiba Y, Mizuki A, Inatomi N, Yamamoto O, Sato S.

J Smooth Muscle Res. 1995 Dec;31(6):492-5. Japanese. No abstract available.

PMID:
8867984
40.

Stimulatory mechanism of EM523-induced contractions in postprandial stomach of conscious dogs.

Shiba Y, Mizumoto A, Inatomi N, Haga N, Yamamoto O, Itoh Z.

Gastroenterology. 1995 Nov;109(5):1513-21.

PMID:
7557133
41.
42.

[Motilide, motilin-like macrolides].

Omura S, Inatomi N, Itoh Z.

Tanpakushitsu Kakusan Koso. 1993 Aug;38(11):1881-90. Review. Japanese. No abstract available.

PMID:
8210432
43.
44.

Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.

Inatomi N, Nagaya H, Takami K, Shino A, Satoh H.

Jpn J Pharmacol. 1991 Apr;55(4):437-51.

46.

EM-523, an erythromycin derivative, and motilin show similar contractile activity in isolated rabbit intestine.

Satoh T, Inatomi N, Satoh H, Marui S, Itoh Z, Omura S.

J Pharmacol Exp Ther. 1990 Sep;254(3):940-4.

PMID:
2395122
47.

Ethanol oxidation by deermice mitochondria under physiologic conditions.

Inatomi N, Ito D, Lieber CS.

Alcohol Clin Exp Res. 1990 Feb;14(1):130-3.

PMID:
2178465
48.

Role of xanthine oxidase in ethanol-induced lipid peroxidation in rats.

Kato S, Kawase T, Alderman J, Inatomi N, Lieber CS.

Gastroenterology. 1990 Jan;98(1):203-10.

PMID:
2293579
49.

An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs.

Inatomi N, Satoh H, Maki Y, Hashimoto N, Itoh Z, Omura S.

J Pharmacol Exp Ther. 1989 Nov;251(2):707-12.

PMID:
2810120
50.

Supplemental Content

Loading ...
Support Center